Abstract
As the healthcare system evolves from a centralized, hospital- and office-based model to an emphasis on patient-centric care delivered in decentralized settings from the community and/or home to low resource settings domestically and internationally, some Point-of-Care Technologies (POCT) have become important and others may soon become important in facilitating care. These portable diagnostic and monitoring devices enable moving care closer to the patient. We review recent developments in a national model to accelerate the development of POCT, specifically the Point-of-Care Technology Research Network (POCTRN), comprising a multi-center scientific network supported by a coordinating center. We summarize the history of the Network, and then describe the primary objectives and key activities of the Network and highlight the role of a new coordinating center providing administrative and infrastructure support. POCTRN is committed to building evidence-based best practices for high-quality translation and commercialization in biomedical engineering to maximize clinical impact of Point-of-Care Technologies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 145-148 |
| Number of pages | 4 |
| Journal | Current Opinion in Biomedical Engineering |
| Volume | 11 |
| DOIs | |
| State | Published - Sep 2019 |
Funding
Additional support for DDM was provided by NIH grants U54HL143541 , R01HL126911 , R01HL126911 , R01HL137734 , R01HL137794 , R01HL135219 , R01HL141434 , and National Science Foundation grant NSF-12-512 . DDM has received research support from Apple , Bristol-Myers Squibb , Flexcon , Samsung , Pfizer , Philips , Biotronik , and Boehringer Ingelheim . DDM has received consulting fees or honoraria from Bristol Myers Squibb , Pfizer , Samsung Electronics , and FlexCon . Additional support for DDM was provided by NIH grants U54HL143541, R01HL126911, R01HL126911, R01HL137734, R01HL137794, R01HL135219, R01HL141434, and National Science Foundation grant NSF-12-512. DDM has received research support from Apple, Bristol-Myers Squibb, Flexcon, Samsung, Pfizer, Philips, Biotronik, and Boehringer Ingelheim. DDM has received consulting fees or honoraria from Bristol Myers Squibb, Pfizer, Samsung Electronics, and FlexCon.C-THAN is “supported by the National Institute of Biomedical Imaging and Bioengineering, Fogarty International Center and the Office of AIDS Research of the National Institutes of Health under Award Number U54EB027049. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” C-THAN is “supported by the National Institute of Biomedical Imaging and Bioengineering , Fogarty International Center and the Office of AIDS Research of the National Institutes of Health under Award Number U54EB027049 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” In 2006, the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Heart Lung and Blood Institute (NHLBI), and National Science Foundation (NSF) convened a workshop called “Improving Health Care Accessibility through Point-of-Care Technologies”' to address healthcare delivery challenges, particularly the fragmentation and inaccessibility of care [ 1 ]. The central workshop theme was that moving medical testing closer to the point at which care was delivered would reduce fragmentation of care and improve accessibility and clinical outcomes.
Keywords
- Collaboration
- Innovation
- Network
- Point-of-Care
- Technology
- Translational research
ASJC Scopus subject areas
- Bioengineering
- Medicine (miscellaneous)
- Biomaterials
- Biomedical Engineering